Funding and Investments

Sep 28, 2018
While food, shelter, and clothing are the primal essentials for life, hope—as embodied by modern medicine—has now become part of that human expectation.
Sep 27, 2018
By BioPharm International Editors
The company plans to lay off approximately 400 employees to support the restructuring of its R&D organization.
Sep 27, 2018
By BioPharm International Editors
GE Healthcare, Cobra Biologics, and the Centre for Process Innovation (CPI) have entered into a collaboration to advance manufacturing of adeno-associated virus vectors for gene therapy.
Sep 26, 2018
By BioPharm International Editors
The National Institute for Health and Care Excellence recently rejected National Health Service’s funding of Kymriah for diffuse large B-cell lymphoma (DLBCL) despite recognizing that the drug has significant clinical benefits.
Sep 20, 2018
By BioPharm International Editors
The biopharmaceutical company will invest approximately $800 million to expand facilities and manufacturing capacity at its campus in Rensselaer County, NY.
Sep 19, 2018
By BioPharm International Editors
The drug particle engineering and nanotechnology company offers a nanotechnology platform that can revive failed drugs in the pharma pipeline.
Sep 10, 2018
By BioPharm International Editors
The collaboration will explore the potential of Dyadic’s gene-expression platform to produce multiple biologic vaccines and drugs.
Jul 27, 2018
By BioPharm International Editors
The National Science Foundation grant will be used to commercialize a synthetic biology platform for cancer drug development.
Jul 03, 2018
By BioPharm International Editors
The pharma major intends to spinoff Alcon as a stand-alone eye-care devices company.
Jul 03, 2018
By BioPharm International Editors
Biogen will pay Samsung BioLogics approximately $700 million to increase its stake in Samsung Bioepis to approximately 49.9%.
native1_300x100
lorem ipsum